Plain-English translation of NCT07619560 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called a "probiotic Y7, tryptophan, and branched-chain amino acid cocktail" to see if it can slow down Parkinson's disease progression in its early stages. Researchers believe that changing the bacteria in your gut may help protect your brain and preserve your movement, thinking, and other functions. You would take this medication daily for 12 weeks while researchers measure how it affects your symptoms and overall disease course.
Recent research suggests that the bacteria living in your gut may play a role in how Parkinson's disease develops and progresses. This trial exists to test whether this medication—a carefully designed probiotic blend—can help slow that progression by improving your gut health, giving people with early Parkinson's disease more time before symptoms worsen.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to either receive the probiotic supplement daily or to a control group for 12 weeks. Either way, you'll have assessments before and after the trial period that measure your movement, thinking, mood, and other symptoms through physical tests, questionnaires, and possibly blood work. You'll need to visit the clinic for these assessments and follow the study instructions carefully throughout the 12-week period.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Taiwan